KDA's Mission
The KDA is about to celebrate its 25th year. The KDA's mission has remained the same. To inform, support, educate, fund research and find a cure for Kennedy's Disease. Help us find a cure. Donate today
News & Events
AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients.
Taipei, May 21, 2025 – AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-controlled, first-in-patient clinical trial of AJ201 in adults with Spinal and Bulbar Muscular Atrophy (SBMA). Conducted across six U.S. clinical sites, the study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AJ201 (ClinicalTrials.gov Identifier: NCT05517603). While not powered to assess efficacy, exploratory endpoints revealed meaningful treatment-related improvements that support continued clinical development. For more information, click here.
-
New research "Kennedy Disease in Latin America: Two New Mexican Cases and a Systematic Review of Regional Reports." To read the article, click here.
-
Kennedy's Disease is an adult-onset disease with symptoms usually appearing between the ages of 30 and 50. However, earlier and later onsets have been recorded. Life expectancy is noted to be at or almost normal. Generally males with this inherited gene develop symptoms, while females with this gene are carriers. For more information click here.
-
Kennedy's Disease support groups connect people living with and/or effected by Kennedy's Disease together for support. To find your group, click here.
-
Need financial help to pay for the Kennedy's Disease DNA test. Use our Contact Us form by clicking here and add “DNA Test” to the subject line. We will send you an application form to be completed by your physician and yourself.
More News
The KDA is delighted to welcome Delery Rice as KDA's first Executive Director who joined the KDA team on October 5, 2026. With more than 20 years of nonprofit leadership experience, Delery brings a wealth of expertise in fundraising, strategic development, disability advocacy, and building partnerships that make a difference in people’s lives.
Experimental drug AJ201 (also called rosolutamide) is moving into a Phase 3 clinical trial for Kennedy's Disease
The Kennedy’s Disease Association (KDA) is launching KD Voices, a new initiative that will give people affected by Kennedy’s Disease an opportunity to share their experiences, perspectives, and priorities directly with pharmaceutical and biotechnology companies developing potential treatments.
